Many well-established companies of the industry or even startups are advancing with methods to produce vaccines in order to find the solution to the pandemic of COVID-19
Here are some of the companies formulating vaccines and treatments in the U.S. for COVID-19:
1- Amgen Inc.and Adaptive Biotechnologies Corp
The collaboration attempts to reveal antibodies that stop or treat COVID-19. “Working with Adaptive and using their viral-neutralizing antibody platform will expedite our ability to bring a promising new medicine into clinical trials as quickly as possible,” -Robert Bradway, Amgen’s chairman, and CEO has stated.
2-BNTX and Pfizer Inc
The vaccine version that they have come up with will be put into clinical trials in late April, in Germany and the U.S. As part of the agreement, Pfizer will pay $185 million upfront, with extra likely later payments of up to $563 million.
BioNTech is also experimenting with the vaccine in collaboration with Shanghai Fosun Pharmaceutical Group Co. Ltd. in China.
On March 31 the FDA approved a mid-stage test for its innovative drug leronlimab in COVID-19 patients. The controlled examination will test the effectiveness and security of leronlimab in 75 patients.
CytoDyn has studied experimental treatment for people with HIV and a form of metastatic breast tumor.
4-Dynavax Technologies Corp
Dynavax’s adjuvant technology can help produce an improved immune response to a vaccine; the biopharmaceutical company is also operating with the University of Queensland, Australia, on vaccine construction through a CEPI deal.
5-Gilead Sciences Inc
Gilead is known for producing the first major cure for Hepatitis-C. The company knows about producing and marketing HIV drugs.
Along with U.S. trials, Gilead is leading a randomized, surveilled clinical trial in Wuhan, experimenting remdesivir as a cure for mild-to-moderate models of pneumonia in people with COVID-19.
The company announced in April it intends to have 500,000 treatment programs completed by October and 1 million by the end of 2020.
6- GlaxoSmithKline GSK
GSK is a leading vaccine maker, having previously produced vaccines for human papillomavirus and the seasonal flu.
Dr. Thomas Breuer, chief medical officer for GSK Vaccines, is directing work on vaccines and the adjuvant platform. Separately, GSK and Vir Biotechnology Inc. declared a contract in early April, in which GSK made a $250 million equity investment in Vir as the two companies work together to develop two of Vir’s experimental therapies, VIR-7831, and VIR-7832 assumed to go to Phase 2 clinical trials someday in 2020.
7-Heat Biologics Inc
The company has revealed that its COVID-19 vaccine candidate had been attached to the World Health Organization’s “draft view” of 41 candidate vaccines. The company lately entered the Alliance for Biosecurity, which may help it “secure government funding to support its rapid development, production, and distribution” of its COVID-19 vaccine.
8-Inovio Pharmaceuticals Inc
Inovio has started experimenting with its vaccine candidate in Phase 1 clinical trial at two sites in the U.S.: The Perelman School of Medicine at the University of Pennsylvania and the Center for Pharmaceutical Research in Kansas City, Mo.
The company started clinical trials in the U.S. with up to 40 participants in April. Inovio stated it assumes to have the first effects from the trial during fall and to have 1 million doses of the vaccine available for further clinical trials or emergency use by the end of the year.
Inoviohas declared a $5 million grant from the Bill & Melinda Gates Foundation to test a delivery device for its vaccine candidate. In late March, Inovio stated that Ology BioservicesInc had received an $11.9 million contract from the Department of Defense to assist the possible production of Inovio’s vaccine candidate for military personnel.
9-Company: Johnson & Johnson
J&J is operating with BARDA to experiment with its vaccine candidate, with each company contributing $1 billion for study and development and the public-health system supporting the Phase 1 trials.
Comparable to GSK, J&J’s AdVac, and PER. C6 technologies are applied to develop the means for a vaccine and improve J&J’s experimental Ebola vaccine. “We are also in discussions with other partners, that if we have a vaccine candidate with potential, we aim to make it accessible to China and other parts of the world,” Dr. Paul Stoffels, J&J’s chief scientific officer, announced in a statement.
J&J also announced in February that it had joined with BARDA on a plan that intends to select existing antiviral medications, among experimental or approved treatments, that may be useful against COVID-19.
The company intends to put its lead vaccine candidate in Phase 1 clinical trial in September.
The first patient in the Phase 1 trial took a dose of the vaccine candidate on March 16. The study is assumed to recruit 45 healthy adult patients, between the ages of 18 and 55 years old, in an open-label Phase I clinical trial to test mRNA-1273 as a vaccine for COVID-19.
It’s supposed to end on June 1, 2021. Participants will be observed for one year. The trial will be carried at Kaiser Permanente Washington Health Research Institute in Seattle.
Novavax, a preclinical biotechnology company, declared Feb. 26 it had various vaccine candidates in preclinical animal subjects. In April, the company stated it had recognized a COVID-19 vaccine candidate, and it intends to start a Phase I clinical study in May.
The first phase of the placebo-controlled investigation will enroll 130 healthy adults; the first step of data from that study is anticipated in July.
12-Company: Regeneron Pharmaceuticals Inc
The company’s VelocImmune platform applies genetically-engineered mice with humanized immune systems in preclinical testing. “We are aiming to have hundreds of thousands of prophylactic doses ready for human testing by the end of August,” said Christos Kyratsous, VP of infectious disease R&D and viral vector technology, who is driving the project.
13-Regeneron Pharmaceuticals and Sanofi
The FDA earlier accepted Kevzara, a treatment produced by Regeneron and Sanofi, as a treatment for rheumatoid arthritis in 2017 as part of a newly settled R&D alliance among the two companies.
The randomized, double-blind, placebo-controlled trial is anticipated to register up to 400 patients. The purpose is to decide if the drug reduces patient fevers and their need for oxygen. The Phase 3 trial will decide if Kevzara stops deaths and reduces the need for mechanical ventilation, oxygen, or hospitalization.
On March 30, the companies announced the first patient in their global trial had been treated. The patient is not located in the U.S., though the Phase 2/3 trial is remaining administered in seven countries, including the U.S.
14-Roche Holding AG
Roche’s Actemra was first licensed in 2010 as a rheumatoid arthritis drug. The Swiss drugmaker has launched a Phase 3 clinical trial judging Actemra as a medication for patients with COVID-19 who have been hospitalized with critical pneumonia.
The company intends to examine patient mortality and need for mechanical ventilation or an intense care unit hold among other principal and secondary endpoints.
15-Sanofi and Translate Bio Inc
Starting Feb. 18, Sanofi is operating with BARDA to examine a preclinical vaccine candidate for COVID-19 applying its recombinant DNA platform.
The French drugmaker earlier served with the organization on flu vaccines.
16-Takeda Pharmaceutical Company Ltd
The Japanese drugmaker announced March 4 it intends to test hyperimmune globulins for people who are at high risk for infection.
Its research will be made in Georgia, Takeda stated it would need access to plasma from people who have overcome COVID-19 or those who have taken a vaccine if one is received.
Dr. Rajeev Venkayya, president of Takeda’s vaccine business, is the co-lead of the company’s COVID-19 response team. Like J&J, Takeda intends to investigate whether other treatments, both experimental or with administrative permission, can be part of a potential solution.
Vaxart was one of the first companies to publish plans to produce a vaccine. In March, the clinical-stage company stated that Emergent BioSolutions will help produce and fabricate its oral vaccine candidate.
The company intends to begin a Phase 1 clinical trial in the U.S. in the second half of 2020.
18-Vir Biotechnology Inc
Vir has been one of the most productive partners in the biotech area throughout the pandemic. The company is run by George Scangos, the former CEO of Biogen.
Beginning Feb. 25, it was stated the collaboration with Shanghai-based WuXi Biologics to test monoclonal antibodies as a medication for COVID-19. If the treatment is accepted, WuXi will capitalize on it in China, while Vir will have marketing priorities for the rest of the world.